Professor Lee Kyung-won of Gyeongsang National University Hospital won the Korean Society of Oncology 'Best Story Award'
Oct 06, 2024
Gyeongsang National University Hospital (Hospital Director Ahn Sung-ki) announced that Professor Lee Kyung-won of the Department of Hematologic Oncology won the 'Best Story Award' at the 2024 International Conference on Oncology (KSMO 2024) held at COEX in Seoul from September 26 to 27.
At this competition, Professor Lee Kyung-won received an award under the theme of 'Prognostic Analysis of YAP1 Gene in Small Cell Lung Cancer'.
Small cell lung cancer is a carcinoma with very limited treatment methods and poor prognosis compared to non-small cell lung cancer. Although there are phase 3 clinical studies that have improved overall survival when immune checkpoint inhibitors are used in conjunction with existing standard cytotoxic chemotherapy, it is a fatal disease in which the median overall survival of small cell lung cancer is difficult to exceed 9 months to 1 year in general.
Recently, Harvard Medical School has introduced molecular genetic subtypes of small cell lung cancer, but no research has been conducted on Korean patients. Therefore, it was confirmed that molecular genetic subtypes of small cell lung cancer could be distinguished through immunohistochemical testing methods, and prognostic analysis according to treatment was performed.
Professor Lee Kyung-won "Through this study, it was confirmed that the expression of the YAP1 gene can be used as a good prognostic factor in patients with small cell lung cancer who received platinum-based chemotherapy. In addition, it is significant that YAP1 is the first in Korea to report that it can be used as a prognostic factor for current standard treatment rather than as a marker for subtype in small cell lung cancer.
At this competition, Professor Lee Kyung-won received an award under the theme of 'Prognostic Analysis of YAP1 Gene in Small Cell Lung Cancer'.
Small cell lung cancer is a carcinoma with very limited treatment methods and poor prognosis compared to non-small cell lung cancer. Although there are phase 3 clinical studies that have improved overall survival when immune checkpoint inhibitors are used in conjunction with existing standard cytotoxic chemotherapy, it is a fatal disease in which the median overall survival of small cell lung cancer is difficult to exceed 9 months to 1 year in general.
Recently, Harvard Medical School has introduced molecular genetic subtypes of small cell lung cancer, but no research has been conducted on Korean patients. Therefore, it was confirmed that molecular genetic subtypes of small cell lung cancer could be distinguished through immunohistochemical testing methods, and prognostic analysis according to treatment was performed.
Professor Lee Kyung-won "Through this study, it was confirmed that the expression of the YAP1 gene can be used as a good prognostic factor in patients with small cell lung cancer who received platinum-based chemotherapy. In addition, it is significant that YAP1 is the first in Korea to report that it can be used as a prognostic factor for current standard treatment rather than as a marker for subtype in small cell lung cancer.
|
bellho@sportschosun.com
